# Cygnaltherapeutics

**Canonical:** https://apis.io/providers/cygnaltherapeutics/  
**Website:** https://equityzen.com/company/cygnaltherapeutics  
**APIs profiled:** 0

Cygnaltherapeutics is a privately held, early‑stage biotechnology company pioneering the field of Exoneural Biology – the neural regulation of cancer, immunity, and regeneration. Founded in 2017 by Flagship Pioneering, the company develops medicines that target neural pathways outside the traditional central‑nervous‑system focus. It operates from Cambridge, Massachusetts and aims to create novel therapeutics by manipulating nerve signaling to treat disease.

## Kin Score — 3.1 / 100 (minimal)

Scored 2026-10-23 under rubric 0.25.0.

| Facet | Score |
|---|---|
| Discoverability | 44.6 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Horizontal (data, software, accessibility, platform)**: 5.9 (matched via fallback).

## Agent readiness — 3.1 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | documented |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## Security (1)

- **Cygnaltherapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Biotechnology, Exoneural Biology, Cancer, Immunology, Regeneration, Cambridge

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/cygnaltherapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.